MediciNova, Inc.  

(Public, NASDAQ:MNOV)   Watch this stock  
Find more results for MNOV
6.62
-0.03 (-0.45%)
After Hours: 6.62 0.00 (0.00%)
Oct 17, 4:49PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.51 - 6.71
52 week 4.40 - 7.78
Open 6.56
Vol / Avg. 58,978.00/98,909.00
Mkt cap 233.99M
P/E     -
Div/yield     -
EPS -0.29
Shares 35.35M
Beta 0.05
Inst. own 26%
Jul 26, 2017
Q2 2017 MediciNova Inc Earnings Call
Jul 27, 2017
Q2 2017 MediciNova Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -29.48% -27.96%
Return on average equity -33.82% -32.30%
Employees 10 -
CDP Score - -

Address

4275 Executive Sq Ste 650
LA JOLLA, CA 92037-1477
United States - Map
+1-858-3731500 (Phone)
+1-858-4040048 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.

Officers and directors

Jeffrey Himawan Ph.D. Independent Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Yuichi Iwaki M.D., Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Ryan Selhorn Chief Financial Officer
Bio & Compensation  - Reuters
Geoffrey G. O'Brien J.D. Vice President
Age: 46
Bio & Compensation  - Reuters
Masatsune Okajima Vice President, Head - Japanese Office
Age: 47
Bio & Compensation  - Reuters
Kazuko Matsuda M.D., Ph.D. Chief Medical Officer
Age: 48
Bio & Compensation  - Reuters
Yoshio Ishizaka Independent Director
Age: 75
Bio & Compensation  - Reuters
Yutaka Kobayashi Independent Director
Age: 51
Bio & Compensation  - Reuters